A review from Peking Union Medical College Hospital lays out a two-tier framework for “Behçet’s spectrum disorders,” aiming to help pediatricians decide which genes to test — and which treatments to try.

Picture a child who keeps coming back to the clinic with fevers that have no clear cause, painful sores in the mouth, and inflammation in the gut. The pattern looks a lot like Behçet’s disease, a form of systemic vasculitis marked by recurrent oral and genital ulcers. But the symptoms do not quite meet the diagnostic criteria. For doctors, cases like this have long been a puzzle — and for families, they can mean years of uncertainty.²

A team from Peking Union Medical College Hospital in Beijing has now published a review in the World Journal of Pediatrics that tries to bring order to that puzzle. The paper maps out a group of conditions called Behçet’s spectrum disorders, or BSD, and proposes a practical framework to help clinicians recognize Behçet-like inflammation early and prioritize genetic testing in children whose symptoms fall outside classic patterns.^1,2

Look-alikes with different biology

Part of the difficulty is that Behçet’s disease often looks different in children. Pediatric cases are frequently partial or atypical. On top of that, a growing list of monogenic autoinflammatory disorders — diseases caused by a mutation in a single gene — produce nearly identical symptoms in the skin, mucous membranes, and gut. Biologically, though, they are distinct conditions, and they call for different treatments. The overlap often leads to misdiagnosis, inappropriate therapy, and prolonged suffering.²

The BSD concept was first introduced in 2020 to link these conditions through the inflammatory pathways they share. What has been missing, the authors argue, is a clinically usable framework for early recognition and genetic prioritization in children.²

A core and a periphery

The review proposes two tiers. The core tier is reserved for monogenic diseases that converge directly on the inflammatory pathways that define Behçet’s. These include HA20, caused by mutations in the TNFAIP3 gene; RELA haploinsufficiency; NFKB1 haploinsufficiency; and ELF4 deficiency. These conditions consistently feature recurrent ulceration of the skin and mucous membranes and disrupt NF-κB or JAK-STAT signaling.²

The peripheral tier includes conditions with partial clinical overlap or more indirect connections to the same pathways, but no single defining gene. Among them are recurrent aphthous stomatitis — the common recurring canker sore — PFAPA syndrome, DADA2, and trisomy 8-associated disease.²

Tying the whole spectrum together, the authors identify NF-κB and JAK-STAT as two central inflammatory hubs, common denominators that give a biological rationale for grouping such varied disorders.² Both are major signaling systems that switch on inflammatory genes.

Drawing the boundary lines

A framework is only as useful as its edges, and the review also spells out what does not belong. The authors distinguish genuine spectrum members from phenotypic mimics such as LIG4 deficiency and mutations in IKBKG, the gene also known as NEMO, which can produce similar symptoms without sharing the same underlying mechanism.² Drawing those lines is meant to sharpen diagnosis and steer families away from unnecessary investigations.

The authors stress that BSD is not meant to replace existing diagnostic criteria for Behçet’s disease. Instead, it offers a mechanism-oriented lens for deciding which children with early-onset or atypical presentations should get genetic testing, and for what.²

“We’re not saying these are all the same disease—they’re not,” the authors said. “But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn’t quite fit Behçet’s criteria, the BSD framework gives us a roadmap for what to test for and why.”²

From trial and error to targeted treatment

The practical payoff is in treatment. Once a specific genetic driver is identified, clinicians can reach for targeted therapies — inhibitors of IL-1, TNF, or JAK, for example — suited to particular subsets of patients, rather than cycling through medications by trial and error.² The authors emphasize that genetic testing is especially valuable in early-onset or atypical cases, where conditions that look alike may respond to very different drugs.²

Beyond the clinic, the authors argue that unifying these disorders under shared pathways could encourage collaborative research, support the search for biomarkers, and pave the way for clinical trials designed around mechanisms rather than symptoms.²

The review describes this as a shift from classifying disease purely by symptoms to a stratified, mechanism-informed approach.² For children with stubborn, unexplained inflammation — and for the parents who have watched them go from specialist to specialist — the hope is simpler: a shorter path to the right diagnosis and the right drug.

The work was supported by China’s National Key R&D Program, the National High Level Hospital Clinical Research Funding program, and the CAMS Innovation Fund for Medical Sciences.²

---

Notes

1. Behçet’s spectrum disorders: genetic and immunological insights into an emerging disease concept. (2026). World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01035-4
2. Zhejiang University. (2026, July 23). Beyond Behçet’s disease: A new genetic framework helps decode pediatric inflammatory disorders [Press release]. EurekAlert! https://www.eurekalert.org/news-releases/1137434